While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFLD and active disease signs (e.g., swollen joint, enthesitis, or psoriatic plaque). It aims to assess the impact of biological therapies on liver disorders, joints, and skin in PsA patients.
Adults with diagnosis of PsA fulfilling the classification for PsA (CASPAR) criteria.
Patients with prior exposure to IL12/23i, IL-17i, JAKi, or TYK2i. Patients with exposure to more than 2 TNFi.
Evidence of other causes of chronic liver disease
Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg).
Previous or current infection with Hepatitis C as defined by presence of hepatitis C virus Abin serum (anti-HCV Ab).
University of California, San Diego
Lead sponsor
Janssen Scientific Affairs, LLC
Collaborator